Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 5/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15315040 | 0.81 | ALDH1A1 (0.37) | RECQLCYP1A2ALDH1A1MEN1KMT2A | |
| SCHEMBL21936822 | 0.80 | RECQL (0.35) | RECQLCYP2C19MEN1KMT2A | |
| SCHEMBL24181342 | 0.79 | TERT (0.42) | CYP1A2ALDH1A1MEN1KMT2A | |
| SCHEMBL2585788 | 0.78 | KDM4E (0.54) | ALDH1A1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL9310833 | 0.77 | PIM1 (0.56) | CYP1A2ALDH1A1CYP2C19KMT2AKDM4E | |
| SCHEMBL6273771 | 0.76 | RECQL (0.37) | RECQLALDH1A1CYP2C19RAB9AMEN1 | |
| SCHEMBL992708 | 0.75 | KMT2A (0.56) | ALDH1A1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL26748191 | 0.74 | P2RX7 (0.42) | P2RX7MEN1KMT2A | |
| SCHEMBL13622757 | 0.74 | RECQL (0.36) | RECQLGRM5ALDH1A1CYP2C19RAB9A | |
| SCHEMBL14996073 | 0.73 | ALDH1A1 (0.34) | CYP1A2ALDH1A1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8771646-B2 | Nicotinic acid and picolinic acid derived near-infrared fluorophores | VISEN MEDICAL, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130272967-A1 | Nicotinic Acid and Picolinic Acid Derived Near-Infrared Fluorophores | VISEN MEDICAL, INC. | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130272967-A1 | Nicotinic Acid and Picolinic Acid Derived Near-Infrared Fluorophores | NAPRT, NAMPT, HCAR2 | RECQL 4793/4885GRM5 551/4885P2RX7 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.